A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design.
about
Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 VaccinationHib Vaccines: Past, Present, and Future PerspectivesStructural and Computational Biology in the Design of Immunogenic Vaccine AntigensA maternal vaccine against group B Streptococcus: past, present, and futureDendritic cells in antifungal immunity and vaccine designBoosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosisRecombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli.The use of glycoinformatics in glycochemistryParasite Carbohydrate Vaccines.Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccinesDevelopment of Streptococcus pneumoniae Vaccines Using Live VectorsInteractions between the intestinal microbiota and innate lymphoid cells.Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection.Defined conjugation of glycans to the lysines of CRM197 guided by their reactivity mapping.Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.Conjugate-like immunogens produced as protein capsular matrix vaccines.Profiling pneumococcal type 3-derived oligosaccharides by high resolution liquid chromatography-tandem mass spectrometry.Intact reducing glycan promotes the specific immune response to lacto-N-neotetraose-BSA neoglycoconjugates.Structurally identical capsular polysaccharide expressed by intact group B streptococcus versus Streptococcus pneumoniae elicits distinct murine polysaccharide-specific IgG responses in vivoDifferential idiotype utilization for the in vivo type 14 capsular polysaccharide-specific Ig responses to intact Streptococcus pneumoniae versus a pneumococcal conjugate vaccineRecent progress in vaccines against fungal diseasesNoninvasive Transdermal Vaccination Using Hyaluronan Nanocarriers and Laser Adjuvant.Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines.Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteinsTLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System.The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites.Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine.Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.Glycomaterials for probing host-pathogen interactions and the immune response.Carbohydrates and T cells: a sweet twosome.Noncovalent association of protein and capsular polysaccharide on bacteria-sized latex beads as a model for polysaccharide-specific humoral immunity to intact gram-positive extracellular bacteriaEnhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.Efficacy of Antibody to PNAG Against Keratitis Caused by Fungal Pathogens.Molecular signatures of antibody responses derived from a systems biology study of five human vaccines
P2860
Q26739685-98A3600B-0EC6-4991-9CC8-B0EF7EA345CEQ26767144-165A583C-FB2B-4E0D-B5AD-BA81D10E8CD9Q26777382-51369B0E-C953-41D3-9E55-99ED6736185EQ26822039-5A82A5EF-29D9-4956-92CF-42E22C81FF84Q27001738-B1F54392-6A94-4A43-81D5-54CE6A7A9A5FQ27315911-019603B1-6CEF-4F11-A9A9-40D6B6736FB8Q27336832-C11B27FB-D8BA-4BE2-92A2-AB3149689A5FQ28727599-4A52D2FE-4148-417A-9AB4-70364CA26A7EQ33785863-7F121183-153B-435D-9CB9-BE8B6F4C3954Q33895627-AB2BAF20-6595-43E1-A16F-A63276C50330Q34049012-7AD06B28-F8B9-469A-867B-5AA43B9649BDQ34316015-12E3FBFE-59BC-4687-8B12-38E117D2B03AQ34397537-D3B9E767-BF66-4AF5-BD0E-B4B466AE0224Q34450382-C8B61CF5-25E7-4692-AFD5-FF2CBD2ED0FEQ34798448-66CC09A5-8833-46D4-8D7D-F2F4EAA165A1Q35018095-F56712B8-8AA8-40B0-A788-ED3BD050A00DQ35116917-708A64FF-B24E-4132-9670-8934D7D33E13Q35126742-8D8B2255-505D-4008-A436-8CED2434AA16Q35189827-3F82C53C-7514-44CC-B9DE-81426AC05905Q35588956-5FCE7171-760B-43EF-94AF-309AB0C930C1Q35897201-91D3E485-6502-4B0A-AD3D-C29F89880FA6Q35980776-3DD9A1AC-14EB-4BC5-A834-985A1E1C354FQ36084183-293080DD-D467-4FF0-9A08-C9EB1FD651CEQ36179629-36061A35-7148-4255-BAA1-1D8BEDEC1E18Q36189410-BD303157-26C2-40CA-BBE7-3EC5E8C1911EQ36287530-3D4F1ED8-091D-4ACF-9CAE-B97B2F33B41EQ36496166-BE5FBA58-3ECC-4C98-9420-8C9A5F7884D6Q36552864-8F86B515-50F6-4400-9240-FF60AF6210C8Q36849935-AFEC3DFA-063C-45EF-BCAE-6C467CC5DFC6Q36894391-A44E1F9B-7EB8-49B5-855D-F3145BCC630EQ36933800-704FEDFE-0FBC-487A-9265-752B6CB48D78Q37074015-E62F5D52-1B67-4D65-80D3-ED88C9F6259EQ37103959-4D99B595-0DC6-4D39-9EA2-AE74A5BC6E40Q37107154-13B61858-CE7C-4164-9407-16310F098672Q37118132-AA7DEF45-99A6-497A-989F-E2A125895A28Q37174323-9DF0A6C3-9B89-453B-99EA-734575E35434Q37335477-7F5DA14D-4139-4D4D-8B75-9605ED4AAFEDQ37353525-D4C9B460-AD74-49DF-96B2-716A5E22CFC4Q37561334-E242C04E-313E-4BB2-BEBF-1B8683651C5BQ37625332-B0968447-940E-4DE2-B5BA-3173D25CE6CF
P2860
A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A mechanism for glycoconjugate ...... plications for vaccine design.
@ast
A mechanism for glycoconjugate ...... plications for vaccine design.
@en
type
label
A mechanism for glycoconjugate ...... plications for vaccine design.
@ast
A mechanism for glycoconjugate ...... plications for vaccine design.
@en
prefLabel
A mechanism for glycoconjugate ...... plications for vaccine design.
@ast
A mechanism for glycoconjugate ...... plications for vaccine design.
@en
P2093
P2860
P356
P1433
P1476
A mechanism for glycoconjugate ...... plications for vaccine design.
@en
P2093
Dennis L Kasper
Fikri Y Avci
Xiangming Li
P2860
P2888
P304
P356
10.1038/NM.2535
P407
P50
P577
2011-11-20T00:00:00Z